RG 7713

Drug Profile

RG 7713

Alternative Names: RG7713

Latest Information Update: 05 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Antipsychotics
  • Mechanism of Action Vasopressin 1a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pervasive child development disorders

Most Recent Events

  • 03 Nov 2015 Efficacy data from a phase I trial in Pervasive child development disorders released by Roche
  • 02 Nov 2015 Roche completes a phase I trial for Pervasive child development disorders in USA
  • 01 Nov 2015 Phase-I clinical trials in Pervasive child development disorders in USA before November 2015 (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top